硼替佐米联合地塞米松治疗多发性骨髓瘤的效果研究  

Bortezomib in combination with dexamethasone for the treatment of multiple myeloma

作　　者：江彬彬[1] 吴燕明[1] 丁刚[1] 

机构地区：[1]安徽医科大学附属巢湖医院,安徽巢湖238000

出　　处：《临床医药实践》2014年第8期563-565,共3页Proceeding of Clinical Medicine

摘　　要：目的:观察硼替佐米联合地塞米松治疗多发性骨髓瘤的疗效和不良反应。方法:16例多发性骨髓瘤(MM)患者采用硼替佐米联合地塞米松(PD)方案化疗,按照欧洲骨髓移植协作组(EMBT)标准判断疗效,并按照美国国立癌症研究院的常规毒性判定标准(NCICTCAE)3.0版判定不良反应。结果:16例多发性骨髓瘤患者,其中4例完全缓解(CR),6例部分缓解(PR),2例轻微反应(MR)。总有效率为75.0%。患者均发生一定程度的不良反应,但对症处理后基本缓解。结论:硼替佐米联合地塞米松治疗多发性骨髓瘤疗效理想,不良反应轻微,患者可耐受。Toinvestigatetheefficacyandsafetyofbortezomibcombinedwithdexamethasoneinthetreatment of patients with multiple myeloma. Methods：Sixteen patients were enrolled in bortezomib chenotherapy combind with dexam-ethasone（ PD）. According to the criteria of the European Cooperative Group for Bone Marrow Transplantation（ EBMT）,and the toxicity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events（ NCICTCAE ） 3. 0. Results：Sixteen cases with multiple myeloma in 4 cases of complete respone（CR）,6 cases of partial respone（PR）,2 ca-ses of minor response（MR）. The total effective rate was 75. 0%. The adverse reactions of patients occurred to some extent,but symptomatic treatment after remission. Conclusion：Bortezomib in combination with dexamethasone is a ideal therapeutic regi-men for MM,The adverse events are light and reversible.

关 键 词：多发性骨髓瘤 硼替佐米 地塞米松 

分 类 号：R733.3[医药卫生—肿瘤]